Choosing breast cancer treatment with biomarker testing
Part of Cancer, Skin clinical trials.
This study helps doctors choose the best first or second treatment for breast cancer that has spread or can't be removed. It uses a blood test to look at your cancer's markers, which may help guide which therapy is right for you. The study is for people with HR-positive, HER2-negative breast cancer who are about to start treatment with hormone therapy plus a CDK4/6 inhibitor, or another type of therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (metastatic) or unresectable breast cancer that is HR-positive and HER2-negative.
- You are planning to start either first-line or second-line treatment with hormone therapy plus a CDK4/6 inhibitor (like ribociclib, palbociclib, or abemaciclib), or another type of therapy not including a CDK4/6 inhibitor with hormone therapy.
- You have not had chemotherapy for metastatic disease, but you may have had chemotherapy for early-stage breast cancer.
- You are 18 years or older.
- You are post-menopausal or are willing to suppress ovarian function, and have an ECOG performance status of 0 to 2, meaning you are fairly active and able to care for yourself.
- You can have measurable or non-measurable disease per standard criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a blood test (DiviTum TKa) to see how well it measures treatment response in people with hormone receptor-positive (HR+) breast cancer that has spread. The test may help doctors know if a treatment is working.
This study looks at why some ER-positive, HER2-negative metastatic breast cancers don’t respond well to CDK4/6 inhibitors combined with hormone therapy. It may help researchers understand resistance and improve future treatment choices for people like you.
This study follows people with hormone receptor–positive, HER2-negative metastatic breast cancer who are taking CDK4/6 inhibitor treatment (with or without an added blood test called DiviTum®). The goal is to see how well the standard treatment is working and whether DiviTum® (a serum TK1 activity test) can help guide monitoring.
This trial uses a blood test to look for tumor DNA in women with a certain type of advanced breast cancer (HR-positive, HER2-low). If the DNA doesn't disappear after starting standard hormone therapy with a CDK4/6 inhibitor, participants may be switched to a targeted drug called T-DXd (trastuzumab deruxtecan).
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This trial tests whether using a blood test for tumor DNA can help doctors decide the best treatment for people with HER2-negative breast cancer that has spread. It focuses on a type of therapy called an antibody-drug conjugate (ADC) and aims to personalize your care.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.